UTP15

UTP15 is a WD-repeat protein that operates at the interface of ribosome biogenesis and gene-expression control, functioning both as a structural scaffold of the small-subunit (SSU) processome and as a transcriptional activator (PMID:24219289, PMID:41361183). As a component of the t-UTP sub-complex, human UTP15 localizes to the fibrillar centers of nucleoli, where it directly binds CIRH1A and WDR43 in vitro; this CIRH1A interaction is suppressed by mitotic phosphorylation of CIRH1A at Thr131 (PMID:24219289). UTP15 is essentially immobile within fibrillar centers, and unlike UTP-B components it remains stably positioned when RNA polymerase I transcription is inhibited, consistent with a transcription-independent scaffolding role in rRNA biogenesis (PMID:24754225). Beyond ribosome biogenesis, in mouse embryonic stem cells UTP15 acts independently of its rRNA role as a key activator of pluripotency-associated transcription: NANOG-regulated transcription enhances UTP15 binding to transcription start sites, increasing Pol II occupancy, and UTP15 promotes assembly of Pol II biomolecular condensates to drive pluripotency gene expression (PMID:41361183). Consistent with an essential developmental function, loss of utp15 in zebrafish triggers p53-dependent apoptosis and vascular patterning defects that are rescued by wild-type mRNA and prevented by p53 knockdown (PMID:21949834).

1. 2011 Medium

   Established that UTP15 is required for embryonic survival and vascular development, and placed p53 as the downstream effector of UTP15 deficiency.

   Evidence Forward genetic screen, morpholino knockdown, mRNA rescue and p53 epistasis in zebrafish embryos with vascular marker imaging

   PMID:21949834

   Open questions at the time

   • Did not define the molecular function of Utp15 driving the phenotype
   • Whether p53 activation reflects nucleolar/ribosome biogenesis stress was not shown
   • No mammalian validation of the vascular phenotype
2. 2013 Medium

   Defined UTP15 as a t-UTP sub-complex member of the SSU processome with direct protein partners and regulated assembly, answering what molecular machine it belongs to.

   Evidence Nuclear matrix fractionation, GFP live-cell imaging, in vitro GST pulldown with CIRH1A/WDR43, and phosphorylation assay with Xenopus egg extract

   PMID:24219289

   Open questions at the time

   • Binding shown in vitro; stoichiometry and architecture within the assembled processome not resolved
   • Functional consequence of the Thr131 phosphorylation on rRNA processing not tested
   • No structural model of the UTP15-CIRH1A-WDR43 interface
3. 2014 Medium

   Showed UTP15 mobility is independent of active rRNA transcription, distinguishing t-UTP from UTP-B behavior and supporting a stable scaffold role.

   Evidence FRAP and GFP imaging with RNA polymerase I inhibition (actinomycin D) in HeLa cells

   PMID:24754225

   Open questions at the time

   • What anchors UTP15 in fibrillar centers is unknown
   • Does not connect immobility to a specific step in rRNA processing
4. 2025 High

   Revealed a moonlighting, rRNA-independent function for UTP15 as a NANOG-downstream activator of pluripotency transcription via Pol II condensate assembly.

   Evidence Nascent RNA profiling, NANOG acute degron, CUT&RUN/ChIP for UTP15 and Pol II at TSSs, condensate imaging, and loss-of-function in mESCs

   PMID:41361183

   Open questions at the time

   • How UTP15 is recruited to TSSs mechanistically is not defined
   • Whether the same domains mediate rRNA scaffolding and TSS binding is unknown
   • Generality beyond pluripotency genes / other cell types not tested

• How UTP15's nucleolar scaffolding role and its nucleoplasmic transcription-activation role are coordinated, and how either connects to the p53-dependent developmental phenotypes, remains unresolved.
• No unified model linking ribosome biogenesis, transcriptional condensate function, and p53 activation
• Structural basis of partner binding unresolved
• No human disease association established in the corpus